Cellular Systems Core

蜂窝系统核心

• 批准号: 10454989
• 负责人: JAMES A. LEDERER
• 金额: $ 26.71万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-11 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10454989
• 关键词: ATAC-seq; Adoption; Animals; Antibodies; Antigens; Area; Arthritis; Autoantigens; B cell repertoire; B-cell receptor repertoire sequencing; Basic Science; Big Data; Bioinformatics; Biology; Boston; CRISPR screen; Categories; Cells; Cellular Indexing of Transcriptomes and Epitopes by Sequencing; Clustered Regularly Interspaced Short Palindromic Repeats; Communities; Complex; Computational Biology; Computer Analysis; Computing Methodologies; Custom; Cytometry; DNA sequencing; Data; Data Analyses; Data Science; Data Set; Detection; Development; Disease; Education; Ensure; Experimental Designs; Face; Genomic DNA; Genomics; Goals; Hospitals; Human; Immunology; Immunophenotyping; Individual; Infrastructure; Institutes; Investments; Joints; Laboratories; Lead; Liquid substance; Logistics; Lupus; Mass Spectrum Analysis; Medical; Medicine; Methodology; Methods; Mission; Pathologist; Pediatric Hospitals; Phage ImmunoPrecipitation Sequencing; Preparation; Proteins; Research; Research Personnel; Resources; Rheumatoid Arthritis; Rheumatology; Sampling; Scanning; Services; System; Systemic Lupus Erythematosus; T-Lymphocyte; Techniques; Technology; Testing; Time; Tissues; Translational Research; Woman; antibody libraries; assay development; base; cell dimension; design; high dimensionality; innovation; member; next generation sequencing; programs; proteogenomics; rheumatologist; service delivery; single-cell RNA sequencing; structured data; success; tissue preparation; tissue processing; tool; transcriptome sequencing; transcriptomics; translational scientist

PROJECT SUMMARY/ABSTRACT – Resource Core 2: Cellular Systems Core Investigators in the Joint Biology Consortium (JBC) share a set of challenges that impede utilization of state-of- the-art technologies for research in arthritis and related diseases. Building on success in the first cycle of the JBC, the Cellular Systems Core (CSC) will leverage local resources and economies of scale to cultivate an integrated set of research tools to serve JBC members. The CSC will provide two broad categories of service. First, the CSC will deliver technologies realized through next-generation sequencing. These include single-cell RNAseq, ATAC-seq, T- and B-cell receptor sequencing, genomic DNA sequencing, spatial transcriptomics, CRISPR-based genomic perturbation screens, and autoantigen detection through PhIP-seq and T-scan. Second, the CSC will deliver tools centered on protein detection. These include optimized cytometry by time of flight (CyTOF), tissue mass cytometry, and Luminex-based screens for economical, customizable detection of cyctokines, antibodies, and other proteins. Resulting data will be analyzed through the new Joint Biology Consortium Bioinformatics Core, providing both high-end big-data analysis and structured education and coaching for JBC members, with the goal of developing a community of investigators conversant with advanced computational methods. This program integrates services available through the Brigham and Women’s Hospital Single-Cell Genomics Core and Center for Data Sciences, the Harvard Medical Area CyTOF Core, the Boston Children’s Hospital Division of Immunology, the Broad Institute’s Genomic Perturbation Platform, and other affiliated cores and labs. Progressive optimization of CSC services – now encompassing both cells and intact tissues – will result further through close affiliation with technical and computational leaders of the Accelerating Medicines Partnership (AMP) consortium in rheumatoid arthritis and lupus, ensuring JBC members access to the latest methodologic advances. Service delivery will be led by a scientific team consisting of Harvard CyTOF director Dr. James Lederer supported by associate directors Dr. Kevin Wei and bioinformatician Dr. Maria Gutierrez- Arcelus. This team will ensure that the logistical investment represented by the Cellular Systems Core continues to accelerate innovative translational arthritis research within the JBC.

项目概要/摘要-资源核心2：蜂窝系统核心 联合生物学联盟（JBC）的研究人员分享了一系列阻碍利用国家生物技术的挑战。 关节炎和相关疾病研究的最先进技术。在第一个周期成功的基础上再接再厉， JBC，蜂窝系统核心（CSC）将利用当地资源和规模经济， 为JBC成员服务的一套综合研究工具。CSC将提供两大类服务。 首先，CSC将通过下一代测序提供技术。其中包括单细胞 RNAseq、ATAC-seq、T细胞和B细胞受体测序、基因组DNA测序、空间转录组学、 基于CRISPR的基因组干扰筛选，以及通过PhIP-seq和T扫描进行的自身抗原检测。 其次，CSC将提供以蛋白质检测为中心的工具。这些包括优化的细胞计数， 飞行（CyTOF）、组织质量细胞术和基于Luminex的屏幕，用于经济、可定制的检测 细胞因子、抗体和其他蛋白质。 结果数据将通过新的联合生物学联盟生物信息学核心进行分析， 为JBC成员提供高端大数据分析和结构化教育和辅导，目标是 发展一个熟悉先进计算方法的研究人员社区。 该计划整合了布里格姆妇女医院单细胞基因组学提供的服务， 核心和数据科学中心，哈佛医学区CyTOF核心，波士顿儿童医院 免疫学部、布罗德研究所的基因组扰动平台和其他附属核心， labs. CSC服务的逐步优化-现在包括细胞和完整组织-将导致 通过与加速药物的技术和计算领导者的密切联系， 类风湿性关节炎和狼疮的合作伙伴关系（AMP）联盟，确保JBC成员获得最新的 方法论的进步服务交付将由哈佛CyTOF主任组成的科学团队领导 博士James Lederer在副主任Kevin Wei博士和生物信息学家Maria Gutierrez博士的支持下， Arcelus该团队将确保以蜂窝系统核心为代表的后勤投资 继续在JBC内加速创新的转化性关节炎研究。